Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
about
Current Landscape of Antiviral Drug DiscoveryClinical Implications of Antiviral Resistance in InfluenzaThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignChemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus InhibitionProgress of small molecular inhibitors in the development of anti-influenza virus agents.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism.The cap-binding site of influenza virus protein PB2 as a drug target.A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In VitroInfluenza antivirals currently in late-phase clinical trial.Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis.Novel Polyanions Inhibiting Replication of Influenza Viruses.A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication.Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.Antiviral therapy for respiratory viral infections in immunocompromised patients.Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit.Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.Molecular Basis of mRNA Cap Recognition by Influenza B Polymerase PB2 Subunit.Current landscape and future prospects of antiviral drugs derived from microbial products.Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease.Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017
P2860
Q26766639-87AC5B55-6763-4980-990E-1D1D8D6D33ECQ26782746-5A427DA9-59F2-4526-8388-99D9B044B9CDQ28071809-A272683B-84CB-4F3F-99BD-600EE573F576Q28833828-27ED46F2-0783-4BB3-B453-B7B3A3775517Q30234943-83E8A487-93E2-4048-B126-CBA7AC32CFE9Q30243907-4A089C27-6409-4A1E-96C8-1AD7F0CD9040Q30371858-59DC217D-82B4-4A2A-8CE3-FAEB7D9D1D65Q30384645-533FC80F-025D-4C37-AB44-CA65E7FA3E04Q30390167-6817CFFB-C3DC-4C9E-B815-7A2D3234A750Q30398099-8B11E419-DC98-4EE3-BC00-BFDFEC6A0053Q30398601-C8A30764-106E-4A7F-A486-DFB61B9BE5F8Q30791826-1160C79C-71DF-4073-B401-C4B36929ADCAQ36730039-78A8090A-4F3F-4C66-8809-B5F2057C0ABCQ38766044-5B9FB29A-5893-4BE9-B8AA-A9F1445B0936Q38912274-99026816-34D8-4373-A126-0D60B004E1CDQ38963385-5468C89E-7C59-46A9-9A62-D228DA490178Q39076394-FC2013E0-2B6F-438F-8367-8358D546DEBDQ40058871-0BB1A8C9-1B13-4C0A-A381-DFD459441D47Q40071053-99B16ADD-A91C-4FAD-91DA-68FB0260C6F8Q40743239-621E1BCA-5A10-4E01-AAF2-3C281B0FFF7EQ41130389-E1DB4C45-E7C7-4F51-AD2F-F86E3903F643Q41919714-48817551-3EFE-40C2-8188-F8ED26C249EFQ45323667-84134C3C-B3B7-4D52-B23C-D85A2702C0FDQ47264095-AB3B2825-249E-4668-A8BE-21E8EA244FABQ47549703-2A936C24-2A28-4F26-947D-BE607A2C6FA8Q47569878-E8AA82B8-7D1E-4762-ACD2-14EDD3F435FEQ47601706-5805173E-26CC-490B-A7C3-FD99F0D35586Q54223806-9464F473-5FC8-471A-820D-EA1F022C9985Q55426854-F787A2B8-DC20-483D-9A35-4C41A1ADA382Q56969102-02D43DDA-E513-49A9-BBA4-C9B5F53B8D38
P2860
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@ast
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@en
type
label
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@ast
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@en
prefLabel
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@ast
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@en
P2093
P2860
P356
P1476
Preclinical activity of VX-787 ...... virus polymerase PB2 subunit.
@en
P2093
Alice W Tsai
Ann D Kwong
Azin Nezami
Chris Bral
Colleen F McNeil
Emanuele Perola
Hamilton B Bennett
Joshua R Leeman
Kumkum Saxena
Marc D Jacobs
P2860
P304
P356
10.1128/AAC.04623-14
P407
P577
2014-12-29T00:00:00Z